Pfenex Announces Pricing of IPO

On July 23, 2014, Pfenex, a San Diego-based biotechnology company, announced the pricing of its initial public offering of 8,333,333 shares of common stock at a price of $6.00 per share. In addition, Pfenex granted underwriters a 30-day option to purchase up to 1,250,000 additional shares of common stock at the IPO price. Wilson Sonsini Goodrich & Rosati is advising Pfenex in the offering.

Pfenex, which was spun out of Dow Chemical in 2009, develops high-value and difficult-to-manufacture proteins, including biosimilar therapeutics, and is currently focused on a potential treatment for patients with retinal diseases.

The WSGR team that advised Pfenex included:

Corporate:
Jeffrey Saper
Dan Koeppen
Zachary Myers

Intellectual Property:
Jeffrey Guise
Matt Bresnahan

Technology Transactions:
Ian Edvalson

For more information, please read Pfenex's press release.